NAS10029,644+0.67%S&P7,651+0.17%GOLD$4,416+0.37%BTC$81,118+6.17%VIX14.81−4.08%live tape · as of 05:00 UTC
The Screen · Healthcare · Drug Manufacturers - General
AbbVie
ABBV · a US exchange · USD · Market cap $439.6B · 57,000 employees
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
FAIL · Does not pass the screen
248.78 USD
At the last full screen 2026-09-08
Screened 2026-09-08 · the tape above runs as of 05:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
AbbVie holds its Accumulation at $248.78. The statistical read favours the buyers, held for 1 days.
As held on the ledger · 2026-09-08
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 1 days
Price at the screen
$248.78
Valuation
70.28 trailing · 15.28 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.28
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
50.39%
Below 33%
Interest-bearing debt is 50.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.20%
Below 33%
Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit.
Pass
Receivables
13.30%
Below 49%
Money owed to the company is 13.3% of assets, under the 49% limit.
Pass
Revenue purity
0.43%
Below 5%
Only 0.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 28% discount to our $319.07 fair value, 10.20% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 28.3% margin of safety to the base estimate.
Third-party analyst targets: 29 covering, consensus Buy. The average target sits +13% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Pharmaceuticals Giant with a Shadow of Debt
Imagine every time a new drug is prescribed, a pharmaceutical giant collects a small fee for its innovation, and that's AbbVie. The company's portfolio includes treatments for autoimmune and inflammatory diseases, with products like Skyrizi and Rinvoq leading the charge. But when we delve into its financials, something sticks out - a substantial debt load that trips our ethical screen. This is why we're avoiding it.
AbbVie's revenue growth of 10% and profit margin of 10% sound promising, and a forward P/E of 16.1x might suggest a bargain in a sector known for high multiples. Yet, the market consensus rating of 'buy' with a median target of $280 per share doesn't account for the elephant in the room - a debt ratio that our ethical screen flags as problematic. This risk overshadows the potential gains, making AbbVie a company to avoid.
Risk sits heavily here, predominantly due to AbbVie's debt ratio, which fails our ethical screen. This is a crucial metric, as high debt can constrain a company's ability to invest in future growth and weather economic storms. While the numbers on the surface might paint a different picture, our ethical-first approach compels us to sidestep the risk. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ABBV trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253.
2026-07-30Markup$259.36+0.0%Entry 12
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-28Markup$259.36+0.0%Entry 11
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-27Markup$259.36+0.0%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-26Markup$259.36+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-25Markup$259.36+1.9%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-24Markup$254.49+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-23Markup$254.49+0.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-20Markup$254.49+12.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253.
2026-07-18Markup$227.23+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
